BioMS Medical announces first quarter 20...( Toronto Stock Ex...)

Toronto Stock Exchange Symbol: MS

EDMONTON, May 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter ended March 31, 2008. BioMS, in partnership with Eli Lilly and Company, is developing dirucotide (also known as MBP8298), a synthetic peptide drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.

"During the quarter, we completed our landmark partnership deal with Eli Lilly and Company," said Kevin Giese, President and CEO of BioMS Medical. "We now look forward to multiple clinical milestones for dirucotide (MBP8298) over the next 24 months. In the near-term, the Data Safety Monitoring Board for our MAESTRO-01 pivotal trial will review data from the first 200 patients in the trial and recommend whether the trial should continue. A positive outcome from this review, anticipated in the third quarter of 2008, is expected to trigger a milestone payment from our new partner."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A pivotal phase II/III trial in Canada and Western Europe

evaluating dirucotide (MBP8298) for the treatment of secondary

progressive MS (SPMS). On January 22, 2007, BioMS announced that the

trial had completed full recruitment of 611 patients at 47 trial

sites in 10 countries. Patients are administered either dirucotide

(MBP8298) or placebo every six months for a period of two years. To

date, there have been eight positive safety reviews from the

Data Safety Monitoring Board (DSMB).

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-
'/>"/>